Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration (...) Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: June 6, 2019 Project Number: RC1127-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of varying treatment sequences of androgen receptor targeted agents in patients with castrate-resistant prostate cancer? What is the comparative cost-effectiveness of varying treatment sequences of androgen

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: September 5, 2019 Project Number (...) : RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details

Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Project Number pCODR 10196 Brand Name TBD Generic Name Darolutamide Tumour Type Genitourinary Indication Non (...) -Metastatic Castration Resistant Prostate Cancer Funding Request In combination with androgen depravation therapy (ADT), for the treatment of patients with non-metastatic castration resistant prostate cancer who are at high risk of developing metastases (high risk defined as prostate-specific antigen doubling time ≤ 10 months) during continuous ADT, and have a good Eastern Cooperative Oncology Group (ECOG) performance status Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Bayer Inc

2019 CADTH - Pan Canadian Oncology Drug Review

5. Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details | CADTH.ca Find the information you need Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Project Number pCODR 10200 Brand Name Erleada Generic Name Apalutamide Tumour Type Genitourinary Indication Metastatic (...) Castration-Sensitive Prostate Cancer Funding Request For the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer Janssen Inc. Sponsor Janssen Inc. Submission Date (Target Date) October 15, 2019 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ October 29, 2019 Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation

2019 CADTH - Pan Canadian Oncology Drug Review

6. Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: October 3, 2019 Project Number: RA1062-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What (...) is the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of cryotherapy for prostate cancer? Key Message Four systematic reviews (including one systematic review with meta-analysis) were identified regarding the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of cryotherapy for prostate cancer. Files

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC)

Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC) 1 Published 07 October 2019 1 SMC2195 enzalutamide 40mg soft capsules (Xtandi®) Astellas Pharma Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent process (...) enzalutamide (Xtandi ® ) is not recommended for use within NHSScotland. Indication under review: The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). In a phase III study in men with high-risk non-metastatic CRPC enzalutamide was superior to placebo for metastasis-free survival. High-risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2 nanograms/mL. Both groups received on-going androgen-deprivation therapy or had undergone

2019 Scottish Medicines Consortium

8. High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness (...) and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: February 14, 2019 Project Number: RC1070-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of high-dose-rate versus low-dose-rate brachytherapy for the treatment of prostate cancer? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated (...) : February 22, 2019 Project Number: RC1069-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hydrogel spacers for patients with prostate cancer? What is the cost-effectiveness of hydrogel spacers for patients with prostate cancer? Key Message Three systematic reviews, one randomized controlled trial (described within two eligible reports), seven cohort studies, two economic evaluations

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report

Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Extract IQWiG Reports – Commission No. N17-04 Interstitial low-dose-rate brachytherapy for localized prostate cancer 1 Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Interstitial low-dose-rate brachytherapy for localized prostate cancer Commissioning agency: Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details

Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details | CADTH.ca Find the information you need Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Project Number pCODR 10201 Brand Name Zytiga (Resubmission) Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed high (...) -risk metastatic castration sensitive prostate cancer without small-cell histologic features. Patients required to have at least two of the three following high-risk factors: Gleason score of 8 or more, at least 3 bone lesions, and presence of visceral metastasis. Less than 3 months of androgen deprivation therapy (or orchiectomy) for metastatic disease. Eligible for abiraterone therapy. Review Status Under Review Pre Noc Submission No NOC Date February 15, 2018 Manufacturer Janssen Inc. Sponsor BC

2019 CADTH - Pan Canadian Oncology Drug Review

12. Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details

Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Project Number pCODR 10149 Brand Name Xtandi Generic Name Enzalutamide Strength 40 mg Tumour Type Genitourinary Indication Non-metastatic castration-resistant (...) prostate cancer Funding Request High risk, non-metastatic castration-resistant prostate cancer Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date December 20, 2018 Manufacturer Astellas Pharma Canada, Inc. Sponsor Astellas Pharma Canada, Inc. Submission Date September 24, 2018 Submission Deemed Complete October 9, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ October 9, 2018 Check-point meeting November 20, 2018 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

13. Zytiga for Prostate Cancer – Details

Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details | CADTH.ca Find the information you need Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details Project Number pCODR 10166 Brand Name Zytiga Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy (...) for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy Review Status Withdrawn Clarification BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue

2019 CADTH - Pan Canadian Oncology Drug Review

14. The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence

The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence "The Effects of a Plant-Based Diet and Stress Reduction Techniques on P" by Amanda Barclay and Jacob McAvoy < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Prostate cancer is the most common cancer affecting men. It is also very common for men (...) to suffer from recurrence after primary therapy is completed. The current most commonly used therapies for prostate cancer recurrence, hormonal therapy and radiation, have significant side effects. It is known that diet influences cancer prevention, progression, and recurrence. A plant-based diet, especially when combined with stress reduction techniques, may be a useful therapeutic option with fewer side effects for men with recurrent prostate cancer. This review examines the effects of a plant-based

2019 Pacific University EBM Capstone Project

15. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. (PubMed)

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.We randomly assigned, in a 1:1 ratio, patients who had (...) with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM

16. Risk of prostate cancer for men fathering through assisted reproduction: nationwide population based register study. (PubMed)

Risk of prostate cancer for men fathering through assisted reproduction: nationwide population based register study. To compare the risk and severity of prostate cancer between men achieving fatherhood by assisted reproduction and men conceiving naturally.National register based cohort study.Sweden from January 1994 to December 2014.1 181 490 children born alive in Sweden during 1994-2014 to the same number of fathers. Fathers were grouped according to fertility status by mode of conception: 20 (...)  618 by in vitro fertilisation (IVF), 14 882 by intra-cytoplasmic sperm injection (ICSI), and 1 145 990 by natural conception.Prostate cancer diagnosis, age of onset, and androgen deprivation therapy (serving as proxy for advanced or metastatic malignancy).Among men achieving fatherhood by IVF, by ICSI, and by non-assisted means, 77 (0.37%), 63 (0.42%), and 3244 (0.28%), respectively, were diagnosed as having prostate cancer. Mean age at onset was 55.9, 55.1, and 57.1 years, respectively. Men who

2019 BMJ

17. Hypofractionation for clinically localized prostate cancer. (PubMed)

Hypofractionation for clinically localized prostate cancer. Using hypofractionation (fewer, larger doses of daily radiation) to treat localized prostate cancer may improve convenience and resource use. For hypofractionation to be feasible, it must be at least as effective for cancer-related outcomes and have comparable toxicity and quality of life outcomes as conventionally fractionated radiation therapy.To assess the effects of hypofractionated external beam radiation therapy compared (...) result in little or no difference in prostate cancer-specific survival [PC-SS] (HR 1.00, 95% CI 0.72 to 1.39; studies = 8, participants = 7946; median follow-up 72 months; low-certainty evidence). For men in the intermediate-risk group undergoing conventional fractionation this corresponds to 976 per 1000 men alive after 6 years and 0 more (44 fewer to 18 more) alive per 1000 men undergoing hypofractionation.We are uncertain about the effect of hypofractionation on late radiation therapy

2019 Cochrane

18. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy.To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy.This was a randomised, open-label, parallel-group (...) alone in patients with positive margins or extracapsular extension.Radiotherapy given immediately after prostate cancer surgery prolongs prostate-specific antigen progression-free survival, but causes more adverse events, when compared with surgery alone.Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2019 EvidenceUpdates

19. Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment

Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment Daily online image-guided radiotherapy (prostate cancer) - Health Technology Wales > Daily online image-guided radiotherapy (prostate cancer) Daily online image-guided radiotherapy (prostate cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale (...) University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER038 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend

2019 Health Technology Wales

20. Darolutamide (Nubeqa) - adult patients with non-metastatic castration resistant prostate cancer

Darolutamide (Nubeqa) - adult patients with non-metastatic castration resistant prostate cancer Drug Approval Package: NUBEQA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NUBEQA Company: Bayer HealthCare Pharmaceuticals Inc. Application Number: 212099 Approval Date: 07/30/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2019 FDA - Drug Approval Package